Biora Therapeutics (BIOR) Proxy Filing summary

Executive summary

• Special Meeting scheduled for November 13, 2024, to address key capital structure and compensation matters.

• Proposals include authorizing share issuances related to convertible notes and warrants, amending the equity incentive plan, and potential adjournment to solicit more proxies.

• Board recommends voting in favor of all proposals to support ongoing operations and strategic flexibility.

Voting matters and shareholder proposals

• Proposal 1 seeks approval to issue shares exceeding 20% of outstanding stock for convertible notes and warrants, as required by Nasdaq rules.

• Proposal 2 requests an increase of 2,500,000 shares to the 2018 Equity Incentive Plan and extends its term to 2034.

• Proposal 3 allows adjournment of the meeting to solicit additional proxies if needed.

• Failure to approve Proposals 1A, 1B, or 1C would require repeated special meetings and could impact funding and operations.

Board of directors and corporate governance

• Board members and key investors have entered into voting agreements to support the proposals.

• Non-employee directors receive a mix of cash and equity compensation, with annual and committee retainers.

• Indemnification agreements are in place for directors and officers.